Another FDA 483 highlighting critical data integrity failures at a sterile manufacturing site in India.

A recent U.S. Food and Drug Administration 483 inspection at Maiva Pharma Pvt. Ltd. (Hosur, Tamil Nadu, India) identified serious deficiencies in the control of original CGMP manuf